This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
While the 30-day stunt was not an officially endorsed marketing campaign by Taco Bell, then CEO Mark King later invited Reid to Taco Bell's headquarters in Irvine, California. Reid was also a guest on an official Taco Bell podcast in 2023, discussing the stunt and its effect on his physical health. In 2023, the company test-marketed a vegan Crunchwrap Supreme in Los Angeles, New York, and Orlando to gauge the potential of a national roll out. Bon Appétit tested a vegan Crunchwrap alongside a non-vegan Crunchwrap purchased at the store in midtown Manhattan and said "the differences between the two were also genuinely difficult to discern." On August 29, 2025, the company announced that it would be abrogating its artificial intelligence-powered drive-thrus due to technical difficulties and "trolling," including one instance where a customer ordered 18,000 waters. According to reports, the AI would erroneously tell customers that the store was out of all ingredients except for soda and sauce packets. There were also reports of the AI bots simply disallowing customers to modify their orders, such as replacing meat with beans. The phenomenon quickly became an internet meme. One video on TikTok appeared to show a customer attempting to order McDonald's food items from Taco Bell, which was allowed by the system. Dane Mathews, the chain's Chief Digital and Technology Officer, told the Wall Street Journal: "We’re learning a lot, I’m going to be honest with you. [...] I can tell you it's a very active conversation inside Taco Bell in partnership with our franchisees.
== Entrepreneurship == Mrksich has been an active entrepreneur over the past twenty years. He co-founded SAMDI Tech in 2011, which uses his label-free assay technology to perform high throughput screens for pharmaceutical companies. SAMDI Tech entered into a partnership with Charles River Laboratories in 2018 and was purchased by CRL in 2023. Mrksich also co-founded WMR Biomedical in 2008, with George Whitesides and Carmichael Roberts to develop resorbable stent materials; this company was renamed Lyra Therapeutics and had an IPO in 2020 (NASDAQ LYRA) and has drug-eluting stents in clinical trials for ear, nose and throat disease, including chronic rhinosinusitis. Mrksich has recently founded ModuMab Therapeutics, which applies his megamolecule technology to creating antibody mimics for a broad range of diseases.
== Susceptibility to infection == Pandemics such as COVID-19 show that people dramatically differ in their susceptibility to infection. This may be because of general health, age, or their immune status, e.g. when they have been infected previously. However, it also has become clear that there are genetic factors which determine susceptibility to infection. For instance, up to 40% of SARS-CoV-2 infections may be asymptomatic, suggesting that many people are naturally protected from disease. Large genetic studies have defined risk factors for severe SARS-CoV-2 infections, and genome sequences from 659 patients with severe COVID-19 revealed genetic variants that appear to be associated with life-threatening disease. One gene identified in these studies is type I interferon (IFN). Autoantibodies against type I IFNs were found in up to 13.7% of patients with life-threatening COVID-19, indicating that a complex interaction between genetics and the immune system is important for natural resistance to Covid. Similarly, mutations in the ERAP2 gene, encoding endoplasmic reticulum aminopeptidase 2, seem to increase the susceptibility to the plague, the disease caused by an infection with the bacteria Yersinia pestis. People who inherited two copies of a complete variant of the gene were twice as likely to have survived the plague as those who inherited two copies of a truncated variant. Susceptibility also determined the epidemiology of infection, given that different populations have different genetic and environmental conditions that affect infections.
The amount of YAN that winemakers will see in their grape musts depends on a number of components including grape variety, rootstock, vineyard soils and viticultural practices (such as the use of fertilizers and canopy management) as well as the climate conditions of particular vintages.
Siege life took its toll on the defending soldiers and civilians, as food began to grow scarce after a few weeks. In Mafeking, Sol Plaatje wrote, "I saw horseflesh for the first time being treated as a human foodstuff." The cities also dealt with constant artillery bombardment, making the streets dangerous. Near the end of the siege of Kimberley, it was expected that the Boers would intensify their bombardment, so Rhodes displayed a notice encouraging people to go down into shafts of the Kimberley Mine for protection. The townspeople panicked, and people surged into the mineshafts constantly for a 12-hour period. Although the bombardment never came, this did nothing to diminish the anxious civilians' distress. The most well-heeled of the townspeople, including Rhodes, sheltered in the Sanatorium, site of the present-day McGregor Museum; the poorer residents, notably the black population, did not have any shelter from shelling. In retrospect, the Boers' decision to commit themselves to sieges (Sitzkrieg) was a mistake and an illustration of their lack of strategic vision. Of the seven sieges in the First Boer War, the Boers had prevailed in none. More importantly, it handed the initiative back to the British and allowed them to recover. Generally throughout the campaign, the Boers were too defensive and passive, wasting the opportunities they had for victory. Yet that passivity testified to the fact they had no desire to conquer British territory, but only to preserve their ability to rule in their own territory.
Sources: en.wikipedia.org
==== MeSH D12.125.095 – amino acids, diamino ==== MeSH D12.125.095.104 – arginine MeSH D12.125.095.104.075 – argininosuccinic acid MeSH D12.125.095.104.095 – benzoylarginine-2-naphthylamide MeSH D12.125.095.104.100 – benzoylarginine nitroanilide MeSH D12.125.095.104.400 – homoarginine MeSH D12.125.095.104.525 – ng-nitroarginine methyl ester MeSH D12.125.095.104.587 – nitroarginine MeSH D12.125.095.104.650 – omega-n-methylarginine MeSH D12.125.095.104.900 – tosylarginine methyl ester MeSH D12.125.095.165 – asparagine MeSH D12.125.095.226 – citrulline MeSH D12.125.095.307 – cystathionine MeSH D12.125.095.369 – cystine MeSH D12.125.095.390 – diaminopimelic acid MeSH D12.125.095.461 – glutamine MeSH D12.125.095.461.700 – proglumide MeSH D12.125.095.533 – homocystine MeSH D12.125.095.647 – lysine MeSH D12.125.095.647.478 – hydroxylysine MeSH D12.125.095.647.575 – lysinoalanine MeSH D12.125.095.647.750 – polylysine MeSH D12.125.095.765 – ornithine MeSH D12.125.095.765.340 – eflornithine
=== Secondary polycythemia === Secondary polycythemia is caused by either natural or artificial increases in the production of erythropoietin, hence an increased production of erythrocytes. Secondary polycythemia in which the production of erythropoietin increases appropriately is called physiologic polycythemia. Conditions which may result in physiologic polycythemia include:
==== Angiotensin-converting-enzyme inhibitors (ACEI) ==== Angiotensin-converting-enzyme inhibitors (ACEI) block the conversion of angiotensin I to angiotensin II by inhibiting the action of angiotensin-converting-enzyme, causing the reduction of blood volume and peripheral vascular resistance.
=== Currency === The new state continued to use the Pound sterling from its inception; there is no reference in the Treaty or in either of the enabling Acts to currency. Nonetheless, and within a few years, the Dáil passed the Coinage Act, 1926 (which provided for a Saorstát [Free State] coinage) and the Currency Act, 1927 (which provided inter alia for banknotes of the Saorstát pound). The new Saorstát pound was defined by the 1927 Act to have exactly the same weight and fineness of gold as was the sovereign at the time, making the new currency pegged at 1:1 with sterling. The State circulated its new national coinage in December 1928, marked Saorstát Éireann and a national series of banknotes. British coinage remained acceptable in the Free State at an equal rate. In 1937, when the Free State was superseded by Ireland (Éire), the pound became known as the "Irish pound" and the coins were marked Éire as from 1939. No coins dated 1938 were struck for circulation in Ireland, but the 1938 1 Penny and Half Crown exists as pattern coins.
Sources: en.wikipedia.org
=== Earlier capitals === Bath, the oldest town in North Carolina, was the first nominal capital of the colony from 1705 until 1722, when Edenton took over the role. The colony had no permanent institutions of government until the new capital, New Bern, was established in 1743.
The most important microscopic feature for identification of mushrooms is the spores. Their color, shape, size, attachment, ornamentation, and reaction to chemical tests often can be the crux of an identification. A spore often has a protrusion at one end, called an apiculus, which is the point of attachment to the basidium, termed the apical germ pore, from which the hypha emerges when the spore germinates. The cell walls of mushrooms are composed mainly of glucans and chitin. Glucans have potential roles in reserving energy, providing structure, cell-to-cell signaling, and cellular protection.
The constriction toward the tip of the Pasteur pipettes may be plugged with a bit of tissue paper or cotton wool to filter off solids from small amounts of liquids. The bulb can be attached and squeezed to help viscous solutions filter more rapidly. With a bit of skill, Pasteur pipettes may also be used for microscale column chromatography. With appropriately fine silica gel, the bulb may be squeezed for microscale flash column chromatography.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.